Ironwood Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
Ironwood Pharmaceuticals's earnings have been declining at an average annual rate of -43.4%, while the Biotechs industry saw earnings growing at 19.7% annually. Revenues have been growing at an average rate of 0.6% per year.
Key information
-43.4%
Earnings growth rate
-43.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 0.6% |
| Return on equity | n/a |
| Net Margin | 2.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Aug 16
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Looks Inexpensive But Perhaps Not Attractive Enough
Jun 27Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC
Jun 20Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Feb 16Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential
Jan 31Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price
Dec 19Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly
Jul 25An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued
Apr 18Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt
Mar 28Ironwood Pharmaceuticals: Rinse, Wash And Repeat
Oct 05These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely
Sep 28Ironwood Pharma falls 7% as Linzess Q2 sales of drug from AbbVie weigh
Jul 29Revenue & Expenses Breakdown
How Ironwood Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 401 | 9 | 153 | 0 |
| 31 Mar 24 | 414 | -1,052 | 149 | 0 |
| 31 Dec 23 | 443 | -1,002 | 142 | 0 |
| 30 Sep 23 | 432 | -952 | 124 | 0 |
| 30 Jun 23 | 427 | -917 | 120 | 0 |
| 31 Mar 23 | 417 | 182 | 118 | 0 |
| 31 Dec 22 | 411 | 175 | 116 | 0 |
| 30 Sep 22 | 421 | 168 | 116 | 0 |
| 30 Jun 22 | 416 | 173 | 115 | 0 |
| 31 Mar 22 | 422 | 527 | 112 | 0 |
| 31 Dec 21 | 414 | 528 | 111 | 0 |
| 30 Sep 21 | 413 | 530 | 116 | 0 |
| 30 Jun 21 | 413 | 509 | 123 | 0 |
| 31 Mar 21 | 398 | 143 | 131 | 0 |
| 31 Dec 20 | 390 | 106 | 140 | 0 |
| 30 Sep 20 | 399 | 111 | 144 | 0 |
| 30 Jun 20 | 427 | 97 | 150 | 0 |
| 31 Mar 20 | 440 | 84 | 158 | 0 |
| 31 Dec 19 | 428 | 59 | 170 | 0 |
| 30 Sep 19 | 433 | 19 | 180 | 0 |
| 30 Jun 19 | 367 | -153 | 189 | 0 |
| 31 Mar 19 | 346 | -173 | 207 | 0 |
| 31 Dec 18 | 347 | -194 | 217 | 0 |
| 30 Sep 18 | 310 | -190 | 227 | 0 |
| 30 Jun 18 | 331 | -71 | 238 | 0 |
| 31 Mar 18 | 315 | -108 | 237 | 0 |
| 31 Dec 17 | 298 | -55 | 230 | 0 |
| 30 Sep 17 | 292 | -143 | 229 | 0 |
| 30 Jun 17 | 271 | -143 | 212 | 0 |
| 31 Mar 17 | 260 | -121 | 191 | 0 |
| 31 Dec 16 | 274 | -82 | 173 | 0 |
| 30 Sep 16 | 240 | -82 | 150 | 0 |
| 30 Jun 16 | 213 | -96 | 135 | 0 |
| 31 Mar 16 | 187 | -123 | 131 | 0 |
| 31 Dec 15 | 150 | -143 | 125 | 0 |
| 30 Sep 15 | 134 | -166 | 124 | 0 |
| 30 Jun 15 | 112 | -161 | 122 | 0 |
| 31 Mar 15 | 91 | -173 | 119 | 0 |
| 31 Dec 14 | 76 | -190 | 117 | 0 |
| 30 Sep 14 | 43 | -204 | 115 | 0 |
| 30 Jun 14 | 31 | -224 | 117 | 0 |
| 31 Mar 14 | 34 | -229 | 119 | 0 |
| 31 Dec 13 | 23 | -273 | 123 | 0 |
Quality Earnings: IRWD has high quality earnings.
Growing Profit Margin: IRWD became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IRWD has become profitable over the past 5 years, growing earnings by -43.4% per year.
Accelerating Growth: IRWD has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: IRWD has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: IRWD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.